# Evolutionary Therapy for Rhabdomyosarcoma

> **NCT04388839** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 12 (actual)

## Conditions studied

- Rhabdomyosarcoma

## Interventions

- **DRUG:** Vincristine
- **DRUG:** Cyclophosphamide
- **DRUG:** Vinorelbine
- **DRUG:** Actinomycin D
- **DRUG:** Cyclophosphamide Pill

## Key facts

- **NCT ID:** NCT04388839
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-29
- **Primary completion:** 2026-08
- **Final completion:** 2027-08
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-11-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04388839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04388839, "Evolutionary Therapy for Rhabdomyosarcoma". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT04388839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*